Emerging drugs for the treatment of inflammatory bowel disease, treatment of influenza, Diabetic Nephropathy

[摘要] For decades, Anti-Tumor Necrosis Factor (TNF) have been the mainstay therapy for Crohn's Disease (CD) and Ulcerative Colitis (UC).With the growing need for highly effective therapy, various therapeutic targets have been introduced, including Anti-Integrins, AntiInterleukin (IL) 12/23, selective anti-IL23, Janus Kinase (JAK) inhibitors, Sphingosine-1-Phosphate (S1P) receptor modulators, and mRNA124 splicing agents. Choosing and sequencing the Inflammatory Bowel Disease (IBD) therapies remains a clinical challenge. Whenconsidering treatment options, the disease phenotype, severity of symptoms, patient comorbidities, and prior drug exposure should all betaken into account. Anti-TNF therapy has been shown to be effective in both UC and CD. The perception that newer biologics have a sloweronset of action is likely exaggerated, and providers should reconsider the need for concurrent corticosteroid therapy. JAK inhibitors providerapid symptom relief in patients with moderate-to-severe UC. Because of safety concerns, it is only recommended as a second-line therapyfor UC. IBD treatment should be personalised, have a quick onset of action, induce long-term clinical and endoscopic remission, and beextremely safe.

[学科分类] 药理学